| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
D-(+)-Phenyllactic acid targets bacterial cell walls or essential bacterial enzymes. Its antibacterial mechanism involves inhibition of bacterial growth. It is effective against both Gram-positive and Gram-negative bacteria.
|
|---|---|
| ln Vitro |
In vitro, D-(+)-Phenyllactic acid exhibits antibacterial activity against a range of Gram-positive bacteria from humans and foodstuffs, as well as Gram-negative bacteria found in humans. Its MIC values vary depending on the bacterial strain. It is produced by Geotrichum candidum and may function as a natural preservative.
|
| ln Vivo |
In vivo activity data for D-(+)-Phenyllactic acid are limited. Its antibacterial activity in vitro suggests potential utility as a food preservative or topical antimicrobial agent. Further in vivo studies are needed to confirm its efficacy and safety.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for D-(+)-Phenyllactic acid is conducted using broth microdilution or agar diffusion methods. Bacterial strains are cultured in appropriate media and incubated with serial dilutions of the compound. The minimum inhibitory concentration (MIC) is determined.
|
| Cell Assay |
D-(+)-Phenyllactic acid is not typically used in cell-based assays, as it targets bacteria. Cytotoxicity assays may be conducted in mammalian cell lines to assess potential toxicity.
|
| Animal Protocol |
In vivo animal studies for D-(+)-Phenyllactic acid are limited. Studies would typically involve administration of the compound to rodents followed by assessment of antibacterial efficacy in infection models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for D-(+)-Phenyllactic acid are limited. The compound is soluble in water. It is expected to be absorbed following oral administration. Further PK studies are needed to fully characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for D-(+)-Phenyllactic acid are limited. As a naturally occurring compound produced by Geotrichum candidum, it is expected to have a favorable safety profile. No significant acute toxicity has been reported.
|
| References | |
| Additional Infomation |
(R)-3-phenyllactic acid is a 3-phenyllactic acid with an (R) configuration at the 2-position. It is a 3-phenyllactic acid and also a (2R)-2-hydroxy monocarboxylic acid. It is the conjugate acid of (R)-3-phenyllactic acid. It is the enantiomer of (S)-3-phenyllactic acid. (2R)-2-hydroxy-3-phenylpropionic acid has been reported in Grosmannia crassivaginata, and relevant data are available. See also: phenylacetic acid (note moved to).
D-(+)-Phenyllactic acid is an antibacterial agent produced by Geotrichum candidum, effective against Gram-positive and Gram-negative bacteria. It is not a drug and has no clinical approval. |
| Molecular Formula |
C9H10O3
|
|---|---|
| Molecular Weight |
166.1739
|
| Exact Mass |
166.062
|
| CAS # |
7326-19-4
|
| Related CAS # |
(S)-2-Hydroxy-3-phenylpropanoic acid;20312-36-1
|
| PubChem CID |
643327
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
331.6±22.0 °C at 760 mmHg
|
| Melting Point |
121-125ºC
|
| Flash Point |
168.5±18.8 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
1.05
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
150
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1)C[C@H](C(=O)O)O
|
| InChi Key |
VOXXWSYKYCBWHO-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C9H10O3/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8,10H,6H2,(H,11,12)/t8-/m1/s1
|
| Chemical Name |
(2R)-2-hydroxy-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~601.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0179 mL | 30.0897 mL | 60.1793 mL | |
| 5 mM | 1.2036 mL | 6.0179 mL | 12.0359 mL | |
| 10 mM | 0.6018 mL | 3.0090 mL | 6.0179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
